Navigation auf zora.uzh.ch

Search ZORA

ZORA (Zurich Open Repository and Archive)

Clinical relevance of ticagrelor monotherapy following 1-month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: Insight from GLOBAL LEADERS trial

Kogame, Norihiro; Chichareon, Ply; De Wilder, Kenneth; Takahashi, Kuniaki; Modolo, Rodrigo; Chang, Chun Chin; Tomaniak, Mariusz; Komiyama, Hidenori; Chieffo, Alaide; Colombo, Antonio; Garg, Scot; Louvard, Yves; Jüni, Peter; Steg, Philippe G; Hamm, Christian; Vranckx, Pascal; Valgimigli, Marco; Windecker, Stephan; Stoll, Hans-Peter; Onuma, Yoshinobu; Janssens, Luc; Serruys, Patrick W (2020). Clinical relevance of ticagrelor monotherapy following 1-month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: Insight from GLOBAL LEADERS trial. Catheterization and Cardiovascular Interventions, 96(1):100-111.

Abstract

BACKGROUND
The aim of this study was to investigate the impact of ticagrelor monotherapy following 1-month dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) for bifurcation lesions.
METHODS
GLOBAL LEADERS was a randomized, superiority, all-comers trial comparing 1-month DAPT with ticagrelor and aspirin followed by 23-month ticagrelor monotherapy (experimental treatment) with standard 12-month DAPT followed by 12-month aspirin monotherapy (reference treatment) in patients treated with a biolimus A9-eluting stent. The primary endpoint was a composite of all-cause death or new Q-wave myocardial infarction (MI) at 2 years.
RESULTS
Among the 15,845 patients included in this subgroup analysis, 2,498 patients (15.8%) underwent PCI for at least one bifurcation lesion. The incidence of the primary endpoint was similar between the bifurcation and nonbifurcation groups (4.7 vs. 4.0%, p = .083). The experimental treatment had no significant effect on the primary endpoint according to the presence/absence of a bifurcation lesion (bifurcation: hazard ratio [HR]: 0.74, 95% confidence interval [CI]: 0.51-1.07; nonbifurcation: HR: 0.90, 95% CI: 0.76-1.07, p for interaction = .343), but was associated with significant reduction in definite or probable stent thrombosis (p for interaction = .022) and significant excess of stroke (p for interaction = .018) when compared with the reference treatment.
CONCLUSIONS
After PCI for bifurcation lesions using 1-month of DAPT followed by ticagrelor monotherapy for 23 months did not demonstrate explicit benefit regarding all-cause death or new Q-wave MI as in the overall trial.

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > Cardiocentro Ticino
Dewey Decimal Classification:610 Medicine & health
Scopus Subject Areas:Health Sciences > Radiology, Nuclear Medicine and Imaging
Health Sciences > Cardiology and Cardiovascular Medicine
Language:English
Date:July 2020
Deposited On:17 Nov 2020 17:29
Last Modified:24 Oct 2024 01:36
Publisher:Wiley-Blackwell Publishing, Inc.
ISSN:1522-1946
OA Status:Closed
Publisher DOI:https://doi.org/10.1002/ccd.28428
PubMed ID:31410968
Full text not available from this repository.

Metadata Export

Statistics

Citations

Dimensions.ai Metrics
15 citations in Web of Science®
18 citations in Scopus®
Google Scholar™

Altmetrics

Authors, Affiliations, Collaborations

Similar Publications